Volume 12, Issue 4 pp. 4367-4379

REVIEW

Open Access

Implications of estrogen and its receptors in colorectal carcinoma

Plabon Kumar Das,

Plabon Kumar Das

Department of Biochemistry and Molecular Biology, University of Rajshahi, Rajshahi, Bangladesh

Institute for Glycomics, Griffith University, Gold Coast, Queensland, Australia

Contribution: Data curation (lead), Writing - original draft (lead)

Search for more papers by this author

Joti Saha,

Joti Saha

Department of Applied Chemistry and Chemical Engineering, University of Rajshahi, Rajshahi, Bangladesh

Contribution: Data curation (supporting)

Search for more papers by this author

Suja Pillai,

Suja Pillai

School of Biomedical Sciences, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia

Contribution: Formal analysis (supporting), Writing - review & editing (supporting)

Search for more papers by this author

Alfred K.-Y. Lam,

Alfred K.-Y. Lam

orcid.org/0000-0003-2771-564X

School of Medicine & Dentistry, Griffith University, Gold Coast, Queensland, Australia

Contribution: Writing - review & editing (supporting)

Search for more papers by this author

Vinod Gopalan,

Vinod Gopalan

School of Medicine & Dentistry, Griffith University, Gold Coast, Queensland, Australia

Contribution: Conceptualization (supporting), Writing - review & editing (supporting)

Search for more papers by this author

Farhadul Islam,

Corresponding Author

Farhadul Islam

[email protected]

orcid.org/0000-0001-5262-4702

Department of Biochemistry and Molecular Biology, University of Rajshahi, Rajshahi, Bangladesh

Institute for Glycomics, Griffith University, Gold Coast, Queensland, Australia

Correspondence

Farhadul Islam, Department of Biochemistry and Molecular Biology, University of Rajshahi, Rajshahi 6205, Bangladesh.

Email: [email protected]

Contribution: Conceptualization (lead), Supervision (lead), Writing - review & editing (lead)

Search for more papers by this author

Plabon Kumar Das,

Plabon Kumar Das

Department of Biochemistry and Molecular Biology, University of Rajshahi, Rajshahi, Bangladesh

Institute for Glycomics, Griffith University, Gold Coast, Queensland, Australia

Contribution: Data curation (lead), Writing - original draft (lead)

Search for more papers by this author

Joti Saha,

Joti Saha

Department of Applied Chemistry and Chemical Engineering, University of Rajshahi, Rajshahi, Bangladesh

Contribution: Data curation (supporting)

Search for more papers by this author

Suja Pillai,

Suja Pillai

School of Biomedical Sciences, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia

Contribution: Formal analysis (supporting), Writing - review & editing (supporting)

Search for more papers by this author

Alfred K.-Y. Lam,

Alfred K.-Y. Lam

orcid.org/0000-0003-2771-564X

School of Medicine & Dentistry, Griffith University, Gold Coast, Queensland, Australia

Contribution: Writing - review & editing (supporting)

Search for more papers by this author

Vinod Gopalan,

Vinod Gopalan

School of Medicine & Dentistry, Griffith University, Gold Coast, Queensland, Australia

Contribution: Conceptualization (supporting), Writing - review & editing (supporting)

Search for more papers by this author

Farhadul Islam,

Corresponding Author

Farhadul Islam

[email protected]

orcid.org/0000-0001-5262-4702

Department of Biochemistry and Molecular Biology, University of Rajshahi, Rajshahi, Bangladesh

Institute for Glycomics, Griffith University, Gold Coast, Queensland, Australia

Correspondence

Farhadul Islam, Department of Biochemistry and Molecular Biology, University of Rajshahi, Rajshahi 6205, Bangladesh.

Email: [email protected]

Contribution: Conceptualization (lead), Supervision (lead), Writing - review & editing (lead)

Search for more papers by this author

First published: 07 October 2022

https://doi.org/10.1002/cam4.5242

Citations: 32

Share a link

Email
Wechat
Bluesky

Abstract

Estrogens have been implicated in the pathogenesis of various cancer types, including colorectal carcinoma (CRC). Estrogen receptors such as ERα and ERβ activate intracellular signaling cascades followed by binding to estrogen, resulting in important changes in cellular behaviors. The nuclear estrogen receptors, i.e. ERβ and ERα are responsible for the genomic actions of estrogens, whereas the other receptor, such as G protein-coupled estrogen receptor (GPER) regulates rapid non-genomic actions, which lead to secondary gene expression changes in cells. ERβ, the predominant estrogen receptor expressed in both normal and non-malignant colonic epithelium, has protective roles in colon carcinogenesis. ERβ may exert the anti-tumor effect through selective activation of pro-apoptotic signaling, increasing DNA repair, inhibiting expression of oncogenes, regulating cell cycle progression, and also by changing the micro-RNA pool and DNA-methylation. Thus, a better understanding of the underlying mechanisms of estrogen and its receptors in CRC pathogenesis could provide a new horizon for effective therapeutic development. Furthermore, using synthetic or natural compounds as ER agonists may induce estrogen-mediated anti-cancer activities against colon cancer. In this study, we report the most recent pre-clinical and experimental evidences related to ERs in CRC development. Also, we reviewed the actions of naturally occurring and synthetic compounds, which have a protective role against CRC development by acting as ER agonist.

1 INTRODUCTION

Estrogens are known to play essential roles in the initiation and progression of multiple tumor types, especially tumors of hormonally regulated tissues such as the breast, endometrium and ovary.^{1, 2} In general, estrogen acts as a cancer-protective hormone through its anti-inflammatory activities; however, the roles of individual estrogen (i.e. nuclear or membrane) receptors are often controversial in colorectal cancer (CRC) genesis.² The functionality of estrogens in cancer is mediated by the nuclear estrogen receptors α and β (ERα and ERβ), as well as by the membrane-bound G protein-coupled estrogen receptor (GPER).¹ ERβ, the most prominent among all the estrogen receptor, acts as a tumor suppressor in CRC along with prognostic significance.³ Expression of ERβ in the intestinal crypts may protect the body from developing cancer.⁴ Thus, downregulation of the ERβ receptor in intestinal mucosa may result in the development of CRC.^{3, 4} A significantly lower level of ERβ was noted in CRC patients with advanced clinical stages (stages III & IV) when compared with early stages (stages I & II) patients. Moreover, deficiency of estrogen receptor α (ERα) along with ERβ modulates colon neoplastic transformation and abnormal mucosal formation in an APC-dependent tumourigenesis model.³ Furthermore, GPER can positively regulates cell proliferation, migration and invasion of colon cancer cells, thus, promoting the pathogenesis and progression of CRC.^{1, 5} By cross talking with other signaling pathways such as RAS/RAF/ERK1/2 and EGFR pathways, GPER may also regulate colonic mobility.⁶ Estrogens and their receptors show either positive or negative roles in the pathogenesis of CRC. A deep understanding of the underlying molecular mechanisms of estrogen and its receptors may provide prospects for improved CRC management. In this review, we discuss the roles of estrogen receptors and their multiple molecular targets in CRC pathogenesis. We also outlined the use of some potential natural or synthetic compounds to target ER-mediated signaling in colon cancer cells to inhibit their proliferation and progression.

2 ROLE OF ESTROGEN RECEPTORS (ERS) IN CRC PATHOGENESIS

2.1 The expression characteristics of ERβ and ERα

Estrogen signaling is mediated primarily by ERα and ERβ, which are encoded by estrogen receptor 1(ESR1) and estrogen receptor 2 (ESR2) genes, respectively.^{7, 8} Estrogen, with its receptors ERβ and ERα regulates genes transcription through genomic and non-genomic responses via activating rapid signal transduction pathways.^{9, 10} Genomic effects of estrogen in CRC begin with an activated ER interacting with either specific DNA sequences, also known as estrogen response elements (ERE) or other transcription factors, including c-Jun and c-Fos.¹¹ Though the interaction of both ERs (ERβ and ERα) with ERE is quite similar, however, ERα interacts with c-Jun and c-Fos of the activating protein-1 complex (AP-1) and transcription factor specificity protein 1 (SP1) more frequently than ERβ. In the case of AP1, binding of estrogen with ERα results in activation of transcription, whereas binding of estrogen with ERβ suppresses transcription by ablation of estrogen from the ERα pathway.^{12, 13} Thus, the predominant ERβ expression switch-off ERα meditated activation of downstream signaling by competitive inhibition. However, ERs can also be phosphorylated and activated by the activated kinase pathway without even binding to estrogen ligand. For example, EGFR can activate the Ras/Raf/MAPK pathway, which simultaneously phosphorylates ERs, thereby resulting in dimerization and ligand-independent activation of target genes expression.^{14, 15}

2.2 Mechanism of actions of ERβ and ERα in CRC pathogenesis

The non-genomic actions of estrogen induced-cell proliferation are triggered by the localization of ERs at the plasma membrane.¹⁰ Palmitoylation of ERα allows them to localize at the plasma membrane and then to interact with caveolin-1.¹⁰ This interaction results in the activation of a rapid signaling cascade associated with cell proliferation upon hormonal stimulation. However, ERβ palmitoylation exhibits opposing effects and minimizes ERα induced changes in cellular physiology. ERβ acts as a substrate for palmitoyl acyltransferase (PAT). This palmitoylation of ERβ allows localizing at the plasma membrane and interacts with caveolin-1. Upon this interaction, unlike ERα, the hormonal stimulation causes increased interaction of ERβ with caveolin-1 and p38 member of the MAPK family. These signaling cascades help estrogen to mediate its anti-proliferative effect in CRC cells by increasing pro-apoptotic signals.¹⁰ In addition, co-expression of ERα with ERβ resulted in a concentration-dependent reduction of ERα-mediated transcription, indicating ERβ as the dominant regulator of estrogen signaling.^{16, 17} ERβ induced growth reduction of colon cancer cells and frequent loss of expression in clinical samples indicated the tumor protective feature of ERβ in colon cancer.^{12, 18-20} Table 1 shows the genes or signaling pathways regulated by ERs in CRC pathogenesis.

TABLE 1. Estrogen receptors and their functions in colon cancer

Receptors	Targets	Functions	References
ERβ	hMLH1	Estrogen binding to ERβ can increase the expression of mismatch repair gene hMLH1 to inhibit cancer cells proliferation	[21]
	p21 and p27	Upregulation of p21 and p27 proteins activate caspase-8 and caspase-9 to induce apoptosis of cancer cells	[22]
	p53 signaling	Causes up-regulation of pro-apoptotic p53 target genes Bax, Noxa, and PUMA	[ 23 ]
	miR-17	Inhibits proliferation of cancer cells by down regulation of oncogene Myc	[24]
	miR-205	Inhibits the expression of PROX1, which subsequently reduces the metastatic potential of cancer cells	[25]
	Cyclin E p21CIP1	Inhibits proliferation by modulating cell cycle components, which subsequently results in G1-S cell cycle arrest	[26
	p45Skp2	Causes inhibition of cellular proliferation by downregulation of cdk2-inhibitor p27Kip1 at posttranscriptional level	[27]
	CyclinD1	Inhibits the proliferation of cancer cells by downregulating the expression of CyclinD1	[27]
	mTOR BNIP3	Suppresses the expression of mammalian target of rapamycin (mTOR) or activates Bcl-2/adenovirus E1B 19-kDa-interacting protein 3 (BNIP3) to promote autophagy in cancer cells	[27]
GPER	Bcl-2-associated X protein, p21, and cleaved caspase-3, Bcl-2, procaspase-3	Induces apoptosis of cancer cells by increasing the expression of Bcl-2-associated X protein, p21, and cleaved caspase-3, and by decreasing the expression of anti-apoptotic factors Bcl-2 and procaspase-3	[6]
	Activating transcription factor 6 (ATF6), X box binding protein 1 (XBP-1) and C/EBP-homologous protein (CHOP)	Increases expression of ATF 4 and 6, X box binding protein 1 (XBP-1) and C/EBP-homologous protein (CHOP)to induce endoplasmic reticulum stress mediated growth arrest and apoptosis in cancer cells	[28]
	Reactive oxygen species (ROS), ERK1/2	Increases the expressions of ROS and also increases ERK1/2 phosphorylation, which results in growth arrest of cancer cells	[28]
	Fatty acid synthase (FASN)	Increases the expression and activity of FASN through EGFR/ERK/c-Fos/AP-1 signaling, which subsequently results in increased growth and migration of cancercells	[29]

In the normal colon, ERβ plays vital roles in maintaining the epithelial architecture, regulating gastrointestinal physiology and in mediating immune responses.³⁰ Reduced ERβ expression has been associated with gut permeability, and most importantly, with colitis, a risk factor for CRC development.³¹ However, there have been limited number of studies on the differential expression of ERα and ERβ in both matched non-neoplastic and cancerous tissues. A study noted that the mRNA expression of ERβ was higher in the normal colonic epithelium at 91.7% than 83.3% in CRC tissue. Whereas the expression of ERα mRNA was lower at 16.6% in non-cancerous colonic epithelium than in CRC tissues, which was 25%.³² An in-vivo study by Wada-Hiraike et al. suggested an increase in epithelial cell proliferation and reduced apoptosis was noted in ERβ knockout mice³³ in comparison to that of control animals. A compartmentalization study of ERα and ERβ expression within the crypt axis suggested that ERβ negatively regulates the expression of ERα as colonic enterocytes differentiate and undergo growth arrest.³ Increased ERβ expression in enterocytes of the ascending crypts causes higher competition with ERα for its ligand, as well as for co-activators, which may restrain ERα actions.³ Also, increased ERβ expression could lead to ERα-ERβ hetero-dimerization, thereby the expression pattern of target genes may alter as in proliferating cells, ERα abundance favors its homo-dimerization.³ This phenomenon reveals an important balance kept in the expression of each ER subtypes and their co-expressions in the cells.¹⁰ A molecular mechanism of ERβ actions has been illustrated in Figure 1. As ERβ is the predominant estrogen receptor and it suppresses ERα activity, therefore this review will focus on the actions of ERβ, along with GPER.

Details are in the caption following the image — **FIGURE 1**
Open in figure viewer PowerPoint

Roles of ERβin CRC pathogenesis. Upon binding to its ligand ERβ becomes activated and transcriptionally upregulates downstream target genes such as FOXO3a. The target genes carry ERβ binding elements such as ERE or AP1. The activated FOXO3a in turn transcriptionally upregulates PUMA, p21, and p27. ERβ also inhibits expression of genes such as *c-Myc* and *p45Skp2*. Moreover, some of the EMT and metastasis genes, such as *β-catenin*, *Slug* and *Twist*, are inhibited by ERβ.

2.3 Roles of ERβ in CRC

2.3.1 ERβ mediated DNA repair

ERβ manifests its anti-carcinogenesis properties in human cells in several ways, firstly via induction of prompt DNA repair capacity and, secondly, by increasing apoptosis of cancer/transformed cells.^{21, 34} Jin et al. found a positive correlation between the increased concentration of serum estrogen level in human colonic epithelial cells and upregulation of DNA mismatch repair gene (hMLH1) expression.²¹ Estrogen induced overexpression of hMLH1 was reversed in ERβ-positive colon cancer cells upon the supplementation of estrogen antagonist (ICI182.780). For example, estrogen-induced hMLH1 overexpression was noted in ERβ-positive COLO205 colon cancer cells, which was later downregulated by estrogen antagonist (ICI182.780) supplementation.²¹ These findings implied that the anti-colonic cancer effect of estrogen might be related to the regulation of hMLH1, suggesting estrogen-mediated DNA repair in cancer cells.

2.3.2 ERβ mediated induction of apoptosis of colon cancer cell

ERβ instigates apoptosis of colon cancer (LoVo) cells by activating p53 (TP53) signaling.²² Estrogen and ERβ induce upregulation of p53 downstream components p21 and p27, which activates caspase-8 and caspase-9, resulting in induction of apoptosis of cancer cells. In addition, overexpression of estrogen and ERβ resulted in downregulation of β-catenin proteins, which subsequently cause the downregulation of its target genes (cyclin D1 and Rb), thereby suppressing cell growth and proliferation non-malignant colonocytes.²³ Furthermore, estrogen-mediated activation of p53 signaling causes up-regulation of pro-apoptotic p53 target genes, including Bax, Noxa, and PUMA, which ultimately switch on the apoptosis of cancer cells.²³

2.3.3 ERβ mediated inhibition of oncogenes in CRC

Additionally, the anti-tumourigenic effect of ERβ in cancer cells could be a combination of downregulation of oncogenes such as PROX1, Myc, and MYB along with increased DNA repair capacity and induction of apoptosis (Figure 2). Expression of ERβ changes micro-RNAs (miRs) pool in colon cancer cells, which in turn, could downregulate the expression of Myc and Prospero homeobox protein-1 (PROX1) oncogenes.^{24, 35, 36} Petrova et al. reported that PROX1 drives the transition from benign adenoma to carcinoma, and silencing of this transcription factor resulted in inhibition of human colorectal tumor growth in vivo.³⁷ It was noted that PROX1downregulation was associated with CRC progression, poor tumor differentiation and low patient survival.³⁶ Further study indicated that ERβ induced PROX1 inhibition via miR-205 expression. Inhibition of PROX1 expression caused reduced metastatic potential of colon cancer cells in vivo.²⁵ Thus, a signaling cascade of ERβ, miR-205 and PROX1in the colorectum may confer protective roles against carcinogenesis. Therefore, it is hypothesized that ERβ protects against tumorigenesis in CRC by enhancing DNA repair and apoptosis while repressing oncogene expression, thereby proliferation and metastasis.

2.3.4 ERβ mediated cell cycle regulation in CRCs

Expression of ERβ could induce altered cell cycle kinetics by regulating the expression of several components, including cyclin E, cyclin D1 etc., in colon cancer cells.^{26, 27, 38} ERβ mediated altered expression of these components causes cell cycle arrest, resulting in reduced proliferation of cancer cells.²⁶ For example, Hartman et al. reported that ERβ over-expression inhibits the proliferation of colon cancer HCT8 cells by decreasing cyclin E expression and by increasing CDK inhibitor p21CIP1 expression. This ERβ mediated changes of cyclin E and CDK inhibitor p21CIP1 causes G1-S phase cell cycle arrest in HCT8 cells.²⁶ Also, a significant reduction of in vivo tumor volume was seen, followed by transplantation of ERβ overexpressing cells.²⁶ Another study noted that c-Myc, a well-known oncogene and commonly overexpressed in a majority of CRCs, was downregulated in the ERβ-expressing cancer cells.²⁷ Furthermore, Wei et al. reported that ERβ played an anti-proliferative role in HCT116 colon cancer cells by impairing the cell cycle but not apoptosis, through downregulating the expression of CyclinD1.²⁷ In CRC, the expression of CyclinD1 was increased significantly when compared with normal colon tissue. However, ERβ overexpression induced CyclinD1 downregulation significantly. The study further confirmed that ERβ mediated inhibition of cell proliferation was not by apoptosis as there was no statistically significant difference in the expression of pro-Caspase-3 and cleaved-Caspase-3 between the control group and the group with higher expression of ERβ.²⁷ Besides, ERβ could inhibit the mammalian target of rapamycin (mTOR) or activate Bcl-2/adenovirus E1B 19-kDa-interacting protein 3 (BNIP3) to promote autophagy in colon cancer (HCT116) cells.²⁷ These results indicate that ERβ-mediated CyclinD1 degradation in the combination of mTOR/BNIP3 deregulation could induce inhibition of cancer cell growth through induction of autophagy followed by cell cycle arrest. Therefore, loss of ERβ expression could be one of the events involved in the development or progression of colon cancer. Thus, devise of approaches or mechanism which could lead the expression of ERβ or keep ERβ expression in colonic epithelium might provide a preventive strategies in the management of patients with CRC in clinical settings.

2.3.5 ERβ-mediated epigenetic regulation of CRCs

miRNA mediated regulations of genes expression play a vital role in proliferation, apoptosis and migration of colon cancer cells.^39-42 Previous studies have reported that ERβ induced alteration of miRs in colon cancer (Table 2), resulting in changes of miRs mediated cellular pathophysiology, which in turn could provide cancer-protective features.^{26, 35, 36} In recent studies, the expressions of 27 miRNAs were changed following ERβ expression in CRC and most of these miRNAs are implicated in the pathogenesis of gastrointestinal cancers.^47-49 Also, many of the mRNA targets of these miRs were concomitantly changed upon ERβ expression. For example, Hur et al. found that miR-200 was strongly downregulated upon ERβ expression, which resulted in increased ZEB1 and decreased E-cadherin expressions. In mammary epithelial cells, restoration of miR-200 expression has been found to inhibit the migration, whereas its downregulation was associated with increased migration in colon cancer cells.⁴³ In addition, supplementation of miR-200c mimics causes increased Myc and its target genes expression, which in turn mediated the progression of CRC.⁴³ ERβ-mediated downregulation of Myc was further enhanced by concomitant downregulation of miR-200a/b.

TABLE 2. ER mediated changes in miRNA pool in CRC

MicroRNA	Expression pattern in CRC	Associated functions	References
miR-205	Downregulated	Inhibits the expression of PROX1, which subsequently reduces the metastatic potential of CRC cells	[25]
miR-200a/b	Downregulated	Decreases ZEB1 and increases E-cadherin expressions	[43]
miR-17	Downregulated	Increases the expression of NCOA3 and CLU, which subsequently decreases metastasis and tumor growth.	[35]
miR-196a-1	Upregulated	Inhibits Annexin A1 mediated anti-tumourigenesis in cancer cells	[44]
miR-19a	Upregulated	Induces tumourigenesis by inhibiting tumor suppressor gene DLC1	[45]
miR-25	Upregulated	Induces tumourigenesis by inhibiting tumor suppressor gene LATS2	[46]

Another miRNA mi-17 is involved in ERβ mediated signaling in colon cancer cells.^{35, 50} miR-17 mediates the upregulation of nuclear receptor co-activator 3 (NCOA3) and clusterin (CLU) followed by ERβ expression. Inverse-correlation between miR-17 and its targets such as NCOA3 and CLU was noted in CRC. miR-17induced reduction of CLU and NCOA3 resulted in enhanced angiogenesis and cell growth in colon cancer cells.^{35, 50}

Annexin A1 (ANXA1) is another target of miRNA that are implicated in colon carcinogenesis. ANXA1 is a calcium-dependent phospholipid-linked protein that has been associated with drug resistance, regulation of cellular differentiation, proliferation and apoptosis.⁴⁴ miR-196a-1 suppresses the anti-tumourigenic activity of ANAX1 by inhibiting its expression. However, ERβ expression resulted in the downregulation of miR-196a-1, which in turn recovers the anti-tumourigenic property of ANAX1. ANAX1 mediates its action by inhibiting nuclear factor-κB and inflammatory response in the colon.⁴⁴ Many tumor suppressors such as Deleted in Liver Cancer 1(DLC1) and Large tumor suppressor, homolog 2 (LATS2), downregulated in colon cancer cells, are upregulated followed by ERβ expression and targeted by miRNAs. For instance, DLC1can inhibit proliferation in colon cancer cells, is a target of miR-19a, whereas, tumor suppressor LATS2 is targeted by miR-25.^{45, 46} Thus, exploring the networks between ERβ-affected miRNAs and their target genes is likely to contribute to elucidating the mechanism of transcriptional regulation by ERβ.

Additionally, expression of ERβ associated with DNA-methylation in patients with CRC by binding to the target DNA, thereby modulate menopausal hormonal therapy, which in turn reduced the risk of CRC development.⁵¹ Also, epigenome-wide analysis of DNA-methylation revealed that ERβ expression associated with promoter methylations of genes involved in CRC pathogenesis.⁵² Furthermore, it was reported that moderate/high expressions of ERβ are associated with overall survival in patients with CRC.⁵² Altogether, discovery of ERβ raises hopes for developing better endocrine therapeutic options for patients with CRC, however, the effective therapeutic modalities targeting ERβ is yet to be established. One of the reason could be the antibodies used for ERβ expression analysis in clinical and preclinical studies are might be unspecific.⁵³ Thus, uses of specific antibodies in preclinical, clinical and validation studies could provide better insight of clinical implication of ERβ expression in patients with CRC.

2.4 GPER in colon cancer cells

G protein-coupled estrogen receptor (GPER) plays essential roles in carcinogenesis by regulating cancer cell growth and survival by a selective interaction with ligands G-1(Figure 3).⁵⁴ GPER associated with the regulation of proliferation and survival not only in estrogen-associated cancers such as breast,^{54, 55} ovarian⁵⁶ or endometrial^{57, 58} but also in other cancers, including CRC and lung cancer.^59-63 It regulates cellular mechanisms such as cell cycle, the stress of the endoplasmic reticulum and apoptosis in colon cancer cells.²⁸ Activation of GPER by G-1 ligands results in cell cycle arrest and inhibition of proliferation in colon cancer cells.²⁸ Accumulation of colon cancer cells in the apoptotic sub-G1 phase and lower mitochondrial membrane polarity followed by GPER activation suggested GPER mediated apoptosis of colon cancer cells. Thus, activation of GPER-mediated signaling plays crucial roles in the proliferation and survival of colon cancer cells.

Endoplasmic reticulum stress, another crucial regulatory phenomenon of growth arrest and apoptosis of cancer cells, is associated with GPER mediated signaling.⁶⁴ Liu et al. reported that expression of several important regulators of endoplasmic reticulum stress such as activating transcription factor 4 (ATF4), activating transcription factor 6 (ATF6), X box-binding protein 1 (XBP-1)and C/EBP-homologous protein (CHOP)was increased, followed by G-1 treatment in colon cancer (HCT116) cells.²⁸ Furthermore, GPER mediated signaling caused elevated generations of reactive oxygen species (ROS) and increased ERK1/2 phosphorylation, which subsequently contributed to the growth arrest of colon cancer cells.²⁸

Additionally, GPER activation affects other cellular behaviors such as migration and invasion in multiple cancer types.^{60, 65-70} Importantly, activation of GPER plays dual roles on (HT-29 and DLD-1) colon cancer cells' invasion and migration.⁶⁷ In normoxic conditions, both G-1 and estrogen inhibited the migration of cancer cells, whereas, in hypoxic conditions, GPER stimulation increased the migration of colon cancer cells.⁶⁷ Another estrogen-regulated oncogene, namely Fatty acid synthase (FASN) acts as a key lipogenic enzyme, affects neoplastic transformation of the cells in the breast, colon and liver.^{29, 71-73} GPER induced elevated expression and activity of FASN through EGFR/ERK/c-Fos/AP-1 signaling, which subsequently resulted in increased growth and migration of colon cancer cells.²⁹ Thus, GPER activity regulates cell motility through multiple complex mechanisms. Down-regulation of GPER in mRNA and protein level was seen in cancer tissue samples compared to adjacent non-neoplastic tissues.²⁸ The downregulation of GPER in CRC patients associated with lymph node metastasis, tumor progression and poorer survival rates of patients with cancers.^{28, 64} Also, epigenetic changes were responsible for GPER downregulation in CRC compared to their adjacent non-neoplastic tissues.²⁸ Two of the vital epigenetic modulations, i.e. promoter methylation and histone H3 deacetylation, were associated with the downregulation of GPER in both in-vitro and in-vivo in CRCs.²⁸

There are some controversies that exist regarding the role of GPER, whether it acts as a tumor suppressor or a tumor promoter in CRC development.^{20, 30} Increased GPER expression was noted in colon cancer cells followed by Nonylphenol (NP), an endocrine disruptor (found in cleaners, plastics, and detergents) treatment, which in turn induces the proliferation of colon cancer cells and inhibited apoptosis in vitro.⁷⁴ Upregulation of Cyclin D1, p-PKA, c-Myc, and proteins that regulate the cell cycle was occurred, followed by NP treatment in colon cancer cells.⁷⁴ Treatment of cells with G15, a GPER inhibitor, abrogated the NP mediated ERK1/2 activation and subsequent cell proliferation.⁷⁴ On the other hand, an in vivo study reported that mice receiving G15 treatment had impaired tumor growth.⁷⁵ The study further confirmed GPER activation by its specific agonist G-1 resulted in decreased proliferation, enhanced cell cycle arrest, mitochondrial apoptosis and endoplasmic reticulum stress in colon cancer cells.⁷⁵ Taken together, it can be suggested that further studies are warranted to confirm the role of GPER mediated signaling in colon cancer cells.

3 NATURAL COMPOUNDS SUPPRESSING CRC TUMOURIGENESIS THROUGH ACTING AS AN ER AGONIST

Selective ER agonists could have the potential to stimulate the tumor suppressor function of ER in CRC. A number of both natural and synthetic ligands for ERβ have shown to play protective roles against CRC development (Table 3). Phytoestrogens and xenoestrogens bind to estrogen receptors preferentially due to their structural similarity to estrogen.²⁷ Following binding, they generate similar or varying effects on cancer cell proliferation and progression depending on the structure of the compounds. Xenoestrogens are the synthetic counterpart of estrogens, varying in structure and activities. These synthetic chemicals are potentially harmful and could predispose human to adverse health effects.⁸¹ On the other hand, phytoestrogens are plant-derived compounds that may have protective roles against CRC development, followed by biding to ERβ.⁸² Pre-clinical studies suggested that plant-derived flavonoids play protective roles against endocrine associated cancers, including CRC.^{76, 83, 84} Diet enriched with various phytoestrogens inhibited the generation of polyps and cryptic adenomas in ovariectomized Apc Min/+ female mice. Moreover, phytoestrogens containing diet dose-dependently inhibited azoxymethane-induced intestinal carcinogenesis by elevating the expression of ERβ in the colonic mucosa.^{85, 86} Another study using female ER-β−/− mice reported that dietary fiber in combination with estrogenic isoflavones might effectively alter the gut microbiota through ERβ, which in turn modifies local inflammatory processes to prevent colonic tumorigenesis.⁸⁷ The roles of a few natural and synthetic ERβ agonist compounds in the inhibition of CRC tumourigenesis is illustrated below.

TABLE 3. Natural or synthetic compounds that inhibit colon cancer cells through estrogen receptor signaling

Compounds	Source	Functions	References
Genistein	Soya product	Acts as an ERβ-specific agonist and exerts anti-proliferative and pro-apoptotic effects by reducing the expression of oncogene p63, PCNA expression and by increasing expression of cleaved cytokeratin-18.	[76]
Quercetin	Leafy vegetables, broccoli, red onions etc.	Causes cell cycle arrest, increases apoptosis, modulates estrogen receptors, regulates signaling pathways, inhibits metastasis and angiogenesis etc. in CRC by binding to cannabinoid CB1 receptor	[77]
Calycosin	Radix astragali	Increases the expression of ERβ and reduces the expression of ERα, insulin-like growth factor receptor (IGF-1R), and p-Akt. Also causes down-regulation of miR-95 to increase the apoptosis of colon cancer cells.	[78]
17β-estradiol	Endogenous	Activates p53 signaling, which results in up-regulation of p21 and p27 proteins.	[79]
Diarylpropionitrile (ERβ ligand)	Synthetic compound	Up-regulation of p21 and p27 proteins resulted in inhibition of their target gene cyclin D1 to inhibit cell proliferation	[79]
Propylpyrazole-triol (ERα ligand)	Synthetic compound	Inhibits cell migration by decreasing the expression of urokinase plasminogen activator (u-PA), tissue-type plasminogen activator (t-PA) and matrix metalloproteinase 9 (MMP-9) as well as matrix metalloproteinase 2/9 (MMP-2/9) activity in colon cancer cells.	[79]
Silibinin	Silybum marianum	Induces cell cycle arrest and apoptosis in vitro in colon cancer cells	[80]

3.1 Genistein

Genistein, one of the isoflavones derived from soy product, has been reported to inhibit proliferation and promotes apoptosis by increasing the expression of ERβ followed by activation of various pathways in cancer cells.⁷⁶ In addition, ovariectomized rats exhibited a significant increase in apoptosis and a reduction in the proliferation of colonocytes, followed by Genistein treatment.⁸⁴

3.2 Quercetin

Quercetin, a natural flavonol found in commonly consumed food items, has been demonstrated inhibitory effects on cancer progression by multiple mechanisms.^{77, 88} Diets containing Quercetin, such as vegetables, fruits, and grains, associated with a reduced risk of colon cancer, which indicated the anti-cancer potential of quercetin in CRC.^{89, 90} Quercetin restrains the expression of cellular estrogen-responsive receptors such as cannabinoid CB1 receptor (CB1-R), a G-protein-coupled cannabinoid receptor associated with the proliferation of colon cancer cell.⁹¹ Quercetin binds to CB1-R and regulates cell growth rate in Caco2 and DLD-1 colon cancer cells. Quercetin showed its anti-cancer effects by causing cell cycle arrest, increasing apoptosis, modulating estrogen receptors, regulating growth signaling, and inhibiting metastasis etc., in CRC.⁹² Quercetin is structurally similar to estrogen, therefore, can effectively bind to the CB1-R, and thereby regulate CRC cell growth and proliferation. A significant increase in the expression levels of CB1-R was noted, followed by quercetin treatment; however, this induction was partially abolished with the use of a specific CB1-R antagonist. These results indicate CB1-R dependent action of quercetin in CRC.

3.3 Calycosin

Calycosin, another plant-derived isoflavone, inhibited the proliferation and induced apoptosis of colon cancer (SW480 and LoVo) cells.⁷⁸ Calycosin increased the expression of ERβ and reduced the expression of ERα, insulin-like growth factor receptor (IGF-1R), and p-Akt. It also caused the down-regulation of miR-95 in cancer cells. It was noted that inhibiting ERβ confined the change of miR-95 expression, which subsequently resulted in increased apoptosis of cancer cells. Furthermore, calycosin significantly inhibited xenograft tumor growth in nude mice model.⁷⁸

3.4 Diarylpropionitrile (DPN)

Estradiol (17β-estradiol) such as diarylpropionitrile (DPN), a selective agonist of ERβ exhibited anti-cancer properties against colon cancer cells.⁷⁹ Hsu et al. reported that treatment of cancer cells with these compound activated p53, which in turn activated p21 and p27 proteins and their downstream signaling. Activation of those cell cycle proteins subsequently reduces the expression of cyclin D1, which ultimately inhibits cell proliferation.⁷⁹ Also, 17β-estradiol and ERβ agonists (DPN) significantly inhibited the expression of urokinase plasminogen activator (u-PA), tissue-type plasminogen activator (t-PA), matrix metalloproteinase 9 (MMP-9) and matrix metalloproteinase 2/9 (MMP-2/9), which in turn inhibited colon cancer cells invasion, migration and metastasis. Pretreatment colon cancer (LoVo) cells with a p53 inhibitor significantly restrained the anti-migration effects of ERβ agonists.⁷⁹ Thus, 17β-estradiol and/or ERβ agonists may have the potential to be used as potent alternative therapeutics in the treatment of human CRC.

3.5 Silibinin

Silibinin, a flavonolignan extracted from Silybum marianum, has strong cancer chemo-preventive properties against various cancers, including colon cancer.^93-99 Agarwal et al. suggested that this compound induced cell cycle arrest and apoptosis in vitro in human colon cells.⁹³ In addition, oral supplementation of silibin into nude mice suppressed HT-29 xenograft growth by inhibiting cell proliferation and angiogenesis.⁸⁰ Also, Silibinin showed cancer-protective activities by preventing azoxymethane (AOM)-induced colonic aberrant crypt foci formation in Fisher 344 rats.¹⁰⁰ However, the underlying mechanism of silibinin in the ER-mediated cancer response needs further investigation. In addition, a clinical trial using natural compounds as ER agonist (Eviendep) was tested to examine the recurrence of adenocarcinoma of colon (NCT01402648). Taken together, targeting estrogen and its receptors with synthetic or natural compounds shows promising opportunities for better management of patients with CRCs.

4 CONCLUSION

This review provides a detail of the current literature on the association of estrogen and estrogen receptors in CRC carcinogenesis and potentiates some compounds to be used to enhance the anti-tumourigenic activity of ERs. Further studies of the estrogen-signaling pathway may increase the knowledge of the underlying mechanism of ER driven protection of CRC pathogenesis. For example, chronic inflammation of the colon (colitis) induced CRC pathogenesis is protected by intestinal epithelium ERβ expression, whereas loss of ERβ expression promoted carcinogenesis in the colorectum.¹⁰¹ In addition, intestinal ERβ expression prevent the development of colitis-associated CRC by regulating the expression of TNFα, a regulator of NFκB signaling network.¹⁰² Thus, modulation of ERs have roles in developing potential anti-cancer drugs in CRCs. Therefore, upregulation of ERβ with specific ligands such as phytoestrogens may help to confer a protective effect in the colon by repressing oncogenic transformation and metastasis.

AUTHOR CONTRIBUTIONS

Plabon Kumar Das: Data curation (lead); writing – original draft (lead). Joti Saha: Data curation (supporting). Suja Pillai: Formal analysis (supporting); writing – review and editing (supporting). Alfred K.-Y. Lam: Writing – review and editing (supporting). Vinod Gopalan: Conceptualization (supporting); writing – review and editing (supporting). Farhadul Islam: Conceptualization (lead); supervision (lead); writing – review and editing (lead).

ACKNOWLEDGMENTS

Authors are thankful to the University of Rajshahi, Bangladesh to provide the supports.

FUNDING INFORMATION

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ETHICS STATEMENT

Not applicable.

Open Research

DATA AVAILABILITY STATEMENT

Data included in article/supplementary material/referenced in the article.

REFERENCES

1Saczko J, Michel O, Chwiłkowska A, Sawicka E, Mączyńska J, Kulbacka J. Estrogen receptors in cell membranes: regulation and signaling. Adv Anat Embryol Cell Biol. 2017; 227: 93-105. doi:10.1007/978-3-319-56895-9_6
10.1007/978-3-319-56895-9_6
PubMed Web of Science® Google Scholar
2StevanatoFilho PR, Aguiar Júnior S, Begnami MD, et al. Estrogen receptor β as a prognostic marker of tumor progression in colorectal cancer with familial adenomatous polyposis and sporadic polyps. Pathol Oncol Res. 2018; 24(3): 533-540. doi:10.1007/s12253-017-0268-5
10.1007/s12253-017-0268-5
CAS PubMed Web of Science® Google Scholar
3Cho NL, Javid SH, Carothers AM, Redston M, Bertagnolli MM. Estrogen receptors alpha and beta are inhibitory modifiers of Apc-dependent tumorigenesis in the proximal colon of min/+ mice. Cancer Res. 2007; 67(5): 2366-2372. doi:10.1158/0008-5472.CAN-06-3026
10.1158/0008-5472.CAN-06-3026
CAS PubMed Web of Science® Google Scholar
4Hasson RM, Briggs A, Carothers AM, et al. Estrogen receptor α or β loss in the colon of min/+ mice promotes crypt expansion and impairs TGFβ and HNF3β signaling. Carcinogenesis. 2014; 35(1): 96-102. doi:10.1093/carcin/bgt323
10.1093/carcin/bgt323
CAS PubMed Web of Science® Google Scholar
5Liang R, Lin Y, Yuan CL, et al. High expression of estrogen-related receptor α is significantly associated with poor prognosis in patients with colorectal cancer. Oncol Lett. 2018; 15(4): 5933-5939. doi:10.3892/ol.2018.8011
10.3892/ol.2018.8011
PubMed Web of Science® Google Scholar
6Jacenik D, Beswick EJ, Krajewska WM, Prossnitz ER. G protein-coupled estrogen receptor in colon function, immune regulation and carcinogenesis. World J Gastroenterol. 2019; 25(30): 4092-4104. doi:10.3748/wjg.v25.i30.4092
10.3748/wjg.v25.i30.4092
CAS PubMed Web of Science® Google Scholar
7Caiazza F, Ryan EJ, Doherty G, Winter DC, Sheahan K. Estrogen receptors andtheir implications in colorectal carcinogenesis. Front Oncol. 2015; 5: 19. doi:10.3389/fonc.2015
10.3389/fonc.2015.00019
PubMed Web of Science® Google Scholar
8Greene GL, Gilna P, Waterfield M, Baker A, Hort Y, Shine J. Sequence and expression of human estrogen receptor complementary DNA. Science. 1986; 231(4742): 1150-1154. doi:10.1126/science.3753802
10.1126/science.3753802
CAS PubMed Web of Science® Google Scholar
9Acconcia F, Totta P, Ogawa S, et al. Survival versus apoptotic 17beta-estradiol effect: role of ER alpha and ER beta activated non-genomic signaling. J Cell Physiol. 2005; 203(1): 193-201. doi:10.1002/jcp.20219
10.1002/jcp.20219
CAS PubMed Web of Science® Google Scholar
10Galluzzo P, Caiazza F, Moreno S, Marino M. Role of ERbeta palmitoylation in the inhibition of human colon cancer cell proliferation. Endocr Relat Cancer. 2007; 14(1): 153-167. doi:10.1677/ERC-06-0020
10.1677/ERC-06-0020
CAS PubMed Web of Science® Google Scholar
11Barzi A, Lenz AM, Labonte MJ, Lenz HJ. Molecular pathways: estrogen pathway in colorectal cancer. Clinical Cancer Res. 2013; 19(21): 5842-5848. doi:10.1158/1078-0432.CCR-13-0325
10.1158/1078-0432.CCR-13-0325
CAS PubMed Web of Science® Google Scholar
12Foley EF, Jazaeri AA, Shupnik MA, Jazaeri O, Rice LW. Selective loss of estrogen receptor beta in malignant human colon. Cancer Res. 2000; 60(2): 245-248.
CAS PubMed Web of Science® Google Scholar
13Paech K, Webb P, Kuiper GG, et al. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science. 1997; 277(5331): 1508-1510. doi:10.1126/science.277.5331.1508
10.1126/science.277.5331.1508
CAS PubMed Web of Science® Google Scholar
14Driggers PH, Segars JH. Estrogen action and cytoplasmic signaling pathways. Part II: the role of growth factors and phosphorylation in estrogen signaling. Trends Endocrinol Metab. 2002; 13(10): 422-427. doi:10.1016/s1043-2760(02)00634-3
10.1016/s1043-2760(02)00634-3
CAS PubMed Web of Science® Google Scholar
15Martin LA, Farmer I, Johnston SR, Ali S, Dowsett M. Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation. Endocr Relat Cancer. 2005; 12(suppl 1): S75-S84. doi:10.1677/erc.1.01023
10.1677/erc.1.01023
CAS PubMed Web of Science® Google Scholar
16Liu MM, Albanese C, Anderson CM, et al. Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression. J Biol Chem. 2002; 277(27): 24353-24360. doi:10.1074/jbc.M201829200
10.1074/jbc.M201829200
CAS PubMed Web of Science® Google Scholar
17Matthews J, Wihlén B, Tujague M, Wan J, Ström A, Gustafsson JA. Estrogen receptor (ER) beta modulates ERalpha-mediated transcriptional activation by altering the recruitment of c-Fos and c-Jun to estrogen-responsive promoters. Mol Endocrinol. 2006; 20(3): 534-543. doi:10.1210/me.2005-0140
10.1210/me.2005-0140
CAS PubMed Google Scholar
18Campbell-Thompson M, Lynch IJ, Bhardwaj B. Expression of estrogen receptor (ER) subtypes and ERbeta isoforms in colon cancer. Cancer Res. 2001; 61(2): 632-640.
CAS PubMed Web of Science® Google Scholar
19Rudolph A, Toth C, Hoffmeister M, et al. Expression of oestrogen receptor β and prognosis of colorectal cancer. Br J Cancer. 2012; 107(5): 831-839. doi:10.1038/bjc.2012.323
10.1038/bjc.2012.323
CAS PubMed Web of Science® Google Scholar
20Sareddy GR, Vadlamudi RK. Cancer therapy using natural ligands that target estrogen receptor beta. Chin J Nat Med. 2015; 13(11): 801-807. doi:10.1016/S1875-5364(15)30083-2
10.1016/S1875-5364(15)30083-2
CAS PubMed Web of Science® Google Scholar
21Jin P, Lu XJ, Sheng JQ, et al. Estrogenstimulates the expression of mismatch repair gene hMLH1 in colonic epithelial cells. Cancer Prev Res (Phila). 2010; 3(8): 910-916. doi:10.1158/1940-6207.CAPR-09-0228
10.1158/1940-6207.CAPR-09-0228
CAS PubMed Web of Science® Google Scholar
22Hsu HH, Cheng SF, Wu CC, et al. Apoptotic effects of over-expressed estrogen receptor-beta on LoVo colon cancer cell is mediated by p53 signalings in a ligand-dependent manner. Chin J Physiol. 2006; 49(2): 110-116.
CAS PubMed Web of Science® Google Scholar
23Weige CC, Allred KF, Armstrong CM, Allred CD. P53 mediates estradiol induced activation of apoptosis and DNA repair in non-malignant colonocytes. J Steroid Biochem Mol Biol. 2012; 128(3–5): 113-120. doi:10.1016/j.jsbmb.2011.10.010
10.1016/j.jsbmb.2011.10.010
CAS PubMed Web of Science® Google Scholar
24Edvardsson K, Nguyen-Vu T, Kalasekar SM, Pontén F, Gustafsson JÅ, Williams C. Estrogen receptor β expression induces changes in the microRNA pool in human colon cancer cells. Carcinogenesis. 2013; 34(7): 1431-1441. doi:10.1093/carcin/bgt067
10.1093/carcin/bgt067
CAS PubMed Web of Science® Google Scholar
25Nguyen-Vu T, Wang J, Mesmar F, et al. Estrogen receptor beta reduces colon cancer metastasis through a novel miR-205—PROX1 mechanism. Oncotarget. 2016; 7(27): 42159-42171. doi:10.18632/oncotarget.9895
10.18632/oncotarget.9895
PubMed Google Scholar
26Hartman J, Edvardsson K, Lindberg K, et al. Tumor repressive functions of estrogen receptor beta in SW480 colon cancer cells. Cancer Res. 2009; 69(15): 6100-6106. doi:10.1158/0008-5472.CAN-09-0506
10.1158/0008-5472.CAN-09-0506
CAS PubMed Web of Science® Google Scholar
27Wei Y, Huang C, Wu H, Huang J. Estrogen receptor Beta (ERβ) mediated-CyclinD1 degradation via autophagy plays an anti-proliferation role in colon cells. Int J Biol Sci. 2019; 15(5): 942-952. doi:10.7150/ijbs.30930
10.7150/ijbs.30930
CAS PubMed Web of Science® Google Scholar
28Liu Q, Chen Z, Jiang G, et al. Epigenetic down regulation of G protein-coupled estrogen receptor (GPER) functions as a tumor suppressor in colorectal cancer. Mol Cancer. 2017; 16(1): 87. doi:10.1186/s12943-017-0654-3
10.1186/s12943-017-0654-3
PubMed Web of Science® Google Scholar
29Santolla MF, Lappano R, De Marco P, et al. G protein-coupled estrogenreceptor mediates the up-regulation of fatty acid synthase induced by17β-estradiol in cancer cells and cancer-associated fibroblasts. J Biol Chem. 2012; 287(52): 43234-43245. doi:10.1074/jbc.M112.417303
10.1074/jbc.M112.417303
CAS PubMed Web of Science® Google Scholar
30Looijer-van Langen M, Hotte N, Dieleman LA, Albert E, Mulder C, Madsen KL. Estrogen receptor-β signaling modulates epithelial barrier function. Am J Physiol Gastrointest Liver Physiol. 2011; 300(4): G621-G626. doi:10.1152/ajpgi.00274.2010
10.1152/ajpgi.00274.2010
CAS PubMed Web of Science® Google Scholar
31Pierdominici M, Maselli A, Varano B, et al. Linking estrogen receptor β expression with inflammatory bowel disease activity. Oncotarget. 2015; 6(38): 40443-40451. doi:10.18632/oncotarget.6217
10.18632/oncotarget.6217
PubMed Google Scholar
32Xie LQ, Yu JP, Luo HS. Expression of estrogen receptor beta in human colorectal cancer. World J Gastroenterol. 2004; 10(2): 214-217. doi:10.3748/wjg.v10.i2.214
10.3748/wjg.v10.i2.214
CAS PubMed Web of Science® Google Scholar
33Wada-Hiraike O, Imamov O, Hiraike H, et al. Role of estrogen receptor beta in colonic epithelium. Proc Natl Acad Sci USA. 2006; 103(8): 2959-2964. doi:10.1073/pnas.0511271103
10.1073/pnas.0511271103
CAS PubMed Web of Science® Google Scholar
34Qiu Y, Waters CE, Lewis AE, Langman MJ, Eggo MC. Oestrogen-induced apoptosis in colonocytes expressing oestrogen receptor beta. J Endocrinol. 2002; 174(3): 369-377. doi:10.1677/joe.0.1740369
10.1677/joe.0.1740369
CAS PubMed Web of Science® Google Scholar
35Edvardsson K, Ström A, Jonsson P, Gustafsson JÅ, Williams C. Estrogen receptor β induces antiinflammatory and antitumorigenic networks in colon cancer cells. Mol Endocrinol. 2011; 25(6): 969-979. doi:10.1210/me.2010-0452
10.1210/me.2010-0452
CAS PubMed Google Scholar
36Skog, M., Bono, P., Lundin, M., et al. Expression and prognostic value of transcription factor PROX1 in colorectal cancer. Br J Cancer. 2011; 105(9): 1346–1351. doi: 10.1038/bjc.2011.297
10.1038/bjc.2011.297
CAS PubMed Web of Science® Google Scholar
37Petrova TV, Nykänen A, Norrmén C, et al. Transcription factor PROX1 induces colon cancer progression by promoting the transition from benign to highly dysplastic phenotype. Cancer Cell. 2008; 13(5): 407-419. doi:10.1016/j.ccr.2008.02.020
10.1016/j.ccr.2008.02.020
CAS PubMed Web of Science® Google Scholar
38Martineti V, Picariello L, Tognarini I, et al. ERbeta is a potent inhibitor of cell proliferation in the HCT8 human colon cancer cell line through regulation of cell cycle components. Endocr Related Cancer. 2005; 12(2): 455-469. doi:10.1677/erc.1.00861
10.1677/erc.1.00861
CAS PubMed Web of Science® Google Scholar
39Gopalan V, Ebrahimi F, Islam F, et al. Tumour suppressor properties of miR-15a and its regulatory effects on BCL2and SOX2 proteins in colorectal carcinomas. Exp Cell Res. 2018; 370(2): 245-253. doi:10.1016/j.yexcr.2018.06.025
10.1016/j.yexcr.2018.06.025
CAS PubMed Web of Science® Google Scholar
40Islam F, Gopalan V, Vider J, et al. MicroRNA-186-5p overexpression modulates colon cancer growth by repressing theexpression of the FAM134B tumour inhibitor. Exp Cell Res. 2017; 357(2): 260-270. doi:10.1016/j.yexcr.2017.05.021
10.1016/j.yexcr.2017.05.021
CAS PubMed Web of Science® Google Scholar
41Islam F, Gopalan V, Vider J, Lu CT, Lam AK. MiR-142-5p act as an oncogenic microRNA in colorectal cancer: clinicopathological and functional insights. Exp Mol Pathol. 2018; 104(1): 98-107. doi:10.1016/j.yexmp.2018.01.006
10.1016/j.yexmp.2018.01.006
CAS PubMed Web of Science® Google Scholar
42Mamoori A, Wahab R, Islam F, et al. Clinical and biological significance of miR-193a-3p targeted KRAS in colorectal cancer pathogenesis. Hum Pathol. 2018; 71: 145-156. doi:10.1016/j.humpath.2017.10.024
10.1016/j.humpath.2017.10.024
CAS PubMed Web of Science® Google Scholar
43Hur K, Toiyama Y, Takahashi M, et al. MicroRNA-200c modulates epithelial-to-mesenchymaltransition (EMT) in human colorectal cancer metastasis. Gut. 2013; 62(9): 1315-1326. doi:10.1136/gutjnl-2011-301846
10.1136/gutjnl-2011-301846
CAS PubMed Web of Science® Google Scholar
44Zhang Z, Huang L, Zhao W, Rigas B. Annexin 1 induced by anti-inflammatorydrugs binds to NF-kappaB and inhibits its activation: anticancer effects invitro and in vivo. Cancer Res. 2010; 70(6): 2379-2388. doi:10.1158/0008-5472.CAN-09-4204
10.1158/0008-5472.CAN-09-4204
CAS PubMed Web of Science® Google Scholar
45Yabuta N, Mukai S, Okada N, Aylon Y, Nojima H. The tumor suppressor Lats2 ispivotal in Aurora A and Aurora B signaling during mitosis. Cell Cycle. 2011; 10(16): 2724-2736. doi:10.4161/cc.10.16.16873
10.4161/cc.10.16.16873
CAS PubMed Web of Science® Google Scholar
46Sivarajasingham NS, Baker R, Tilsed JV, Greenman J, Monson JR, Cawkwell L. Identifying a region of interest in site- and stage-specific colon cancer onchromosome 13. Ann Surg Oncol. 2003; 10(9): 1095-1099. doi:10.1245/aso.2003.03.004
10.1245/aso.2003.03.004
PubMed Web of Science® Google Scholar
47Luo X, Burwinkel B, Tao S, Brenner H. MicroRNA signatures: novel biomarkerfor colorectal cancer? Cancer Epidemiol, Biomarkers Prev. 2011; 20(7): 1272-1286. doi:10.1158/1055-9965.EPI-11-0035
10.1158/1055-9965.EPI-11-0035
CAS PubMed Web of Science® Google Scholar
48Panarelli NC, Yantiss RK. MicroRNA expression in selected carcinomas of theGastrointestinal tract. Patholog Res Int. 2011; 2011:124608. doi:10.4061/2011/124608
10.4061/2011/124608
PubMed Google Scholar
49Slaby O, Svoboda M, Michalek J, Vyzula R. MicroRNAs in colorectal cancer:translation of molecular biology into clinical application. Mol Cancer. 2009; 8: 102. doi:10.1186/1476-4598-8-102
10.1186/1476-4598-8-102
CAS PubMed Web of Science® Google Scholar
50Dews M, Fox JL, Hultine S, et al. The myc-miR-17~92 axisblunts TGF{beta} signaling and production of multiple TGF{beta}-dependentantiangiogenic factors. Cancer Res. 2010; 70(20): 8233-8246. doi:10.1158/0008-5472.CAN-10-2412
10.1158/0008-5472.CAN-10-2412
CAS PubMed Web of Science® Google Scholar
51Neumeyer S, Popanda O, Butterbach K, et al. DNA methylation profiling to explore colorectal tumor differences according to menopausal hormone therapy use in women. Epigenomics. 2019; 11(16): 1765-1778.
10.2217/epi-2019-0051
CAS PubMed Web of Science® Google Scholar
52Neumeyer S, Popanda O, Edelmann D, et al. Genome-wide DNA methylation differences according to oestrogen receptor beta status in colorectal cancer. Epigenetics. 2019; 14(5): 477-493.
10.1080/15592294.2019.1595998
PubMed Web of Science® Google Scholar
53Andersson S, Sundberg M, Pristovsek N, et al. Insufficient antibody validation challenges oestrogen receptor beta research. Nat Commun. 2017; 8:15840. doi:10.1038/ncomms15840
10.1038/ncomms15840
CAS PubMed Web of Science® Google Scholar
54Zekas E, Prossnitz ER. Estrogen-mediated inactivation of FOXO3a by the Gprotein-coupled estrogen receptor GPER. BMC Cancer. 2015; 15: 702. doi:10.1186/s12885-015-1699-6
10.1186/s12885-015-1699-6
PubMed Web of Science® Google Scholar
55Filardo EJ. A role for G-protein coupled estrogen receptor (GPER) inestrogen-induced carcinogenesis: dysregulated glandular homeostasis, survivaland metastasis. J Steroid Biochem Mol Biol. 2018; 176: 38-48. doi:10.1016/j.jsbmb.2017.05.005
10.1016/j.jsbmb.2017.05.005
CAS PubMed Web of Science® Google Scholar
56Smith HO, Arias-Pulido H, Kuo DY, et al. GPR30 predicts poor survival forovarian cancer. Gynecol Oncol. 2009; 114(3): 465-471. doi:10.1016/j.ygyno.2009.05.015
10.1016/j.ygyno.2009.05.015
CAS PubMed Web of Science® Google Scholar
57Petrie WK, Dennis MK, Hu C, et al. G protein-coupled estrogen receptor-selective ligands modulate endometrial tumor growth. Obstet Gynecol Int. 2013; 2013:472720. doi:10.1155/2013/472720
10.1155/2013/472720
CAS PubMed Google Scholar
58Smith, H.O., Leslie, K.K., Singh, M., Qualls, C.R., Revankar, C.M., Joste, N.E., Prossnitz, E.R. (2007). GPR30: a novel indicator of poor survival for endometrial carcinoma. Am J Obstet Gynecol, 196(4), 386.e1-389; discussion 386.e9-11. doi:10.1016/j.ajog.2007.01.004
10.1016/j.ajog.2007.01.004
PubMed Web of Science® Google Scholar
59Bustos V, Nolan ÁM, Nijhuis A, et al. GPER mediates differential effects of estrogen on colon cancer cell proliferation and migration under normoxic and hypoxic conditions. Oncotarget. 2017; 8(48): 84258-84275. doi:10.18632/oncotarget.20653
10.18632/oncotarget.20653
PubMed Google Scholar
60Hao J, Bao X, Jin B, et al. Ca2⁺channel subunit α 1D promotes proliferation and migration of endometrial cancercells mediated by 17β-estradiol via the G protein-coupled estrogen receptor. FASEB J. 2015; 29(7): 2883-2893. doi:10.1096/fj.14-265603
10.1096/fj.14-265603
CAS PubMed Web of Science® Google Scholar
61Huff MO, Todd SL, Smith AL, et al. Arsenite and cadmium activate MAPK/ERK via membrane estrogen receptors and G-protein coupled estrogen receptor signaling in human lung adenocarcinoma cells. Toxicol Sci. 2016; 152(1): 62-71. doi:10.1093/toxsci/kfw064
10.1093/toxsci/kfw064
CAS PubMed Web of Science® Google Scholar
62Liu C, Liao Y, Fan S, et al. G-protein-coupled estrogen receptor antagonist G15 decreases estrogen-induced development of non- small cell lung cancer. Oncol Res. 2019; 27(3): 283-292. doi:10.3727/096504017X15035795904677
10.3727/096504017X15035795904677
PubMed Web of Science® Google Scholar
63Pisano A, Santolla MF, De Francesco EM, et al. GPER, IGF-IR, and EGFR transduction signaling are involved in stimulatory effects of zinc in breast cancer cells and cancer-associated fibroblasts. Mol Carcinog. 2017; 56(2): 580-593. doi:10.1002/mc.22518
10.1002/mc.22518
CAS PubMed Web of Science® Google Scholar
64Sano R, Reed JC. ER stress-induced cell death mechanisms. Biochim Biophys Acta. 2013; 1833(12): 3460-3470. doi:10.1016/j.bbamcr.2013.06.028
10.1016/j.bbamcr.2013.06.028
CAS PubMed Web of Science® Google Scholar
65Castillo Sanchez R, Gomez R, Perez Salazar E. Bisphenol A induces migrationthrough a GPER-, FAK-, Src-, and ERK2-dependent pathway in MDA-MB-231 breast cancer cells. Chem Res Toxicol. 2016; 29(3): 285-295. doi:10.1021/acs.chemrestox.5b00457
10.1021/acs.chemrestox.5b00457
CAS PubMed Web of Science® Google Scholar
66Chen ZJ, Wei W, Jiang GM, et al. Activation of GPER suppresses epithelial mesenchymal transition oftriple negative breast cancer cells via NF-κB signals. Mol Oncol. 2016; 10(6): 775-788. doi:10.1016/j.molonc.2016.01.002
10.1016/j.molonc.2016.01.002
CAS PubMed Web of Science® Google Scholar
67Deng Q, Jiang G, Wu Y, et al. GPER/hippo-YAP signal is involved in bisphenol S induced migration of triple negative breast cancer (TNBC) cells. J Hazard Mater. 2018; 355: 1-9. doi:10.1016/j.jhazmat.2018.05.013
10.1016/j.jhazmat.2018.05.013
CAS PubMed Web of Science® Google Scholar
68François CM, Wargnier R, Petit F, et al. 17β-estradiol inhibits spreading of metastatic cells from granulosa cell tumors through a non-genomic mechanism involving GPER1. Carcinogenesis. 2015; 36(5): 564-573. doi:10.1093/carcin/bgv041
10.1093/carcin/bgv041
CAS PubMed Web of Science® Google Scholar
69Liang S, Chen Z, Jiang G, et al. Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-κB/IL-6 signals. Cancer Lett. 2017; 386: 12-23. doi:10.1016/j.canlet.2016.11.003
10.1016/j.canlet.2016.11.003
CAS PubMed Web of Science® Google Scholar
70Yan Y, Jiang X, Zhao Y, Wen H, Liu G. Role of GPER on proliferation, migration and invasion in ligand-independent manner in human ovarian cancer cell line SKOV3. Cell Biochem Funct. 2015; 33(8): 552-559. doi:10.1002/cbf.3154
10.1002/cbf.3154
PubMed Web of Science® Google Scholar
71Che L, Pilo MG, Cigliano A, et al. Oncogene dependent requirement of fatty acid synthase in hepatocellular carcinoma. Cell Cycle. 2017; 16(6): 499-507. doi:10.1080/15384101.2017.1282586
10.1080/15384101.2017.1282586
CAS PubMed Web of Science® Google Scholar
72Corominas-Faja B, Vellon L, Cuyàs E, et al. Clinical and therapeutic relevance of themetabolic oncogene fatty acid synthase in HER2⁺ breast cancer. Histol Histopathol. 2017; 32(7): 687-698. doi:10.14670/HH-11-830
10.14670/HH-11-830
CAS PubMed Web of Science® Google Scholar
73Van de Sande T, Roskams T, Lerut E, et al. High-level expression of fatty acid synthase in human prostate cancer tissues is linked to activation and nuclear localization of Akt/PKB. J Pathol. 2005; 206(2): 214-219. doi:10.1002/path.1760
10.1002/path.1760
CAS PubMed Web of Science® Google Scholar
74Lee JW, Han HK, Park S, Moon EY. Nonylphenol increases tumor formation andgrowth by suppressing gender-independent lymphocyte proliferation and macrophageactivation. Environ Toxicol. 2017; 32(6): 1679-1687. doi:10.1002/tox.22385
10.1002/tox.22385
CAS PubMed Web of Science® Google Scholar
75Xie M, Liang JL, Huang HD, Wang MJ, Zhang T, Yang XF. Low doses of nonylphenol promote growth of colon cancer cells through activation of ERK1/2 via G protein–coupled receptor 30. Cancer Res Treat. 2019; 51(4): 1620-1631. doi:10.4143/crt.2018.340
10.4143/crt.2018.340
CAS PubMed Web of Science® Google Scholar
76Qi W, Weber CR, Wasland K, Savkovic SD. Genistein inhibits proliferation of colon cancer cells by attenuating a negative effect of epidermal growth factor on tumor suppressor FOXO3 activity. BMC Cancer. 2011; 11: 219. doi:10.1186/1471-2407-11-219
10.1186/1471-2407-11-219
CAS PubMed Web of Science® Google Scholar
77Sak K. Site-specific anticancer effects of dietary flavonoid quercetin. Nutr Cancer. 2014; 66(2): 177-193. doi:10.1080/01635581.2014.864418
10.1080/01635581.2014.864418
CAS PubMed Web of Science® Google Scholar
78Zhao X, Li X, Ren Q, Tian J, Chen J. Calycosin induces apoptosis in colorectal cancer cells, through modulating the ERβ/MiR-95 and IGF-1R, PI3K/Akt signaling pathways. Gene. 2016; 591(1): 123-128. doi:10.1016/j.gene.2016.07.012
10.1016/j.gene.2016.07.012
CAS PubMed Web of Science® Google Scholar
79Hsu HH, Kuo WW, Ju DT, et al. Estradiol agonists inhibit human LoVo colorectal-cancer cell proliferation and migration through p53. World J Gastroenterol. 2014; 20(44): 16665-16673. doi:10.3748/wjg.v20.i44.16665
10.3748/wjg.v20.i44.16665
CAS PubMed Web of Science® Google Scholar
80Singh RP, Gu M, Agarwal R. Silibinin inhibits colorectal cancer growth by inhibiting tumor cell proliferation and angiogenesis. Cancer Res. 2008; 68(6): 2043-2050. doi:10.1158/0008-5472.CAN-07-6247
10.1158/0008-5472.CAN-07-6247
CAS PubMed Web of Science® Google Scholar
81Bolli A, Bulzomi P, Galluzzo P, Acconcia F, Marino M. Bisphenol A impairsestradiol-induced protective effects against DLD-1 colon cancer cell growth. IUBMB Life. 2010; 62(9): 684-687. doi:10.1002/iub.370
10.1002/iub.370
CAS PubMed Web of Science® Google Scholar
82Williams C, DiLeo A, Niv Y, Gustafsson JÅ. Estrogen receptor beta as target for colorectal cancer prevention. Cancer Lett. 2016; 372(1): 48-56. doi:10.1016/j.canlet.2015.12.009
10.1016/j.canlet.2015.12.009
CAS PubMed Web of Science® Google Scholar
83Guo JY, Li X, Browning JD Jr, et al. Dietary soy isoflavones and estrone protect ovariectomized ERalphaKO and wild-type mice from carcinogen-induced colon cancer. J Nutr. 2004; 134(1): 179-182. doi:10.1093/jn/134.1.179
10.1093/jn/134.1.179
CAS PubMed Web of Science® Google Scholar
84Schleipen B, Hertrampf T, Fritzemeier KH, et al. ERβ-specific agonists and genistein inhibit proliferation and induce apoptosis in the large and small intestine. Carcinogenesis. 2011; 32(11): 1675-1683. doi:10.1093/carcin/bgr188
10.1093/carcin/bgr188
CAS PubMed Web of Science® Google Scholar
85Niv Y. Estrogen receptor β expression and colorectal cancer: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2015; 27(12): 1438-1442. doi:10.1097/MEG.0000000000000471
10.1097/MEG.0000000000000471
CAS PubMed Web of Science® Google Scholar
86Zou Y, Xin Q, Wang Y, Cai Y, Ma D. Isoflavone and its metabolite equol inhibit development of azoxymethane-induced colorectal tumors and modulate proliferation of colon carcinoma cells. Int J Clin Exp Med. 2019; 12(1): 461-469.
CAS Web of Science® Google Scholar
87Menon R, Watson SE, Thomas LN, et al. Diet complexity and estrogen receptor β status affect the composition of the murine intestinal microbiota. Appl Environ Microbiol. 2013; 79(18): 5763-5773. doi:10.1128/AEM.01182-13
10.1128/AEM.01182-13
CAS PubMed Web of Science® Google Scholar
88Khan F, Niaz K, Maqbool F, et al. Molecular targets underlying the anticancer effects of quercetin: an update. Nutrients. 2016; 8(9): 529. doi:10.3390/nu8090529
10.3390/nu8090529
PubMed Web of Science® Google Scholar
89Aoyama N, Kawado M, Yamada H, et al. Low intake of vegetables and fruits and risk of colorectal cancer: the Japan collaborative cohort study. J Epidemiol. 2014; 24(5): 353-360. doi:10.2188/jea.je20130195
10.2188/jea.je20130195
PubMed Web of Science® Google Scholar
90Turati F, Rossi M, Pelucchi C, Levi F, La Vecchia C. Fruit and vegetables and cancer risk: a review of southern European studies. Br J Nutr. 2015; 113(suppl 2): S102-S110. doi:10.1017/S0007114515000148
10.1017/S0007114515000148
CAS PubMed Web of Science® Google Scholar
91Refolo MG, D'Alessandro R, Malerba N, et al. Anti proliferative and pro apoptotic effects of flavonoid quercetin are mediated by CB1 receptor in human colon cancer cell lines. J Cell Physiol. 2015; 230(12): 2973-2980. doi:10.1002/jcp.25026
10.1002/jcp.25026
CAS PubMed Web of Science® Google Scholar
92Darband SG, Kaviani M, Yousefi B, et al. Quercetin: a functional dietary flavonoid with potential chemo-preventive properties in colorectal cancer. J Cell Physiol. 2018; 233(9): 6544-6560. doi:10.1002/jcp.26595
10.1002/jcp.26595
CAS PubMed Web of Science® Google Scholar
93Agarwal C, Singh RP, Dhanalakshmi S, et al. Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells. Oncogene. 2003; 22(51): 8271-8282. doi:10.1038/sj.onc.1207158
10.1038/sj.onc.1207158
CAS PubMed Web of Science® Google Scholar
94Chittezhath M, Deep G, Singh RP, Agarwal C, Agarwal R. Silibinin inhibits cytokine-induced signaling cascades and down-regulates inducible nitric oxide synthase in human lung carcinoma A549 cells. Mol Cancer Ther. 2008; 7(7): 1817-1826. doi:10.1158/1535-7163.MCT-08-0256
10.1158/1535-7163.MCT-08-0256
CAS PubMed Web of Science® Google Scholar
95Kroll DJ, Shaw HS, Oberlies NH. Milk thistle nomenclature: why it matters in cancer research and pharmacokinetic studies. Integr Cancer Ther. 2007; 6(2): 110-119. doi:10.1177/1534735407301825
10.1177/1534735407301825
CAS PubMed Web of Science® Google Scholar
96Rajamanickam S, Kaur M, Velmurugan B, Singh RP, Agarwal R. Silibininsuppresses spontaneous tumorigenesis in APC min/+ mouse model by modulating beta-catenin pathway. Pharm Res. 2009; 26(12): 2558-2567. doi:10.1007/s11095-009-9968-1
10.1007/s11095-009-9968-1
CAS PubMed Web of Science® Google Scholar
97Singh RP, Agarwal R. Mechanisms and preclinical efficacy of silibinin in preventing skin cancer. Eur J Cancer. 2005; 41(13): 1969-1979. doi:10.1016/j.ejca.2005.03.033
10.1016/j.ejca.2005.03.033
CAS PubMed Web of Science® Google Scholar
98Singh RP, Agarwal R. Prostate cancer chemoprevention by silibinin: bench to bedside. Mol Carcinog. 2006; 45(6): 436-442. doi:10.1002/mc.20223
10.1002/mc.20223
CAS PubMed Web of Science® Google Scholar
99Tyagi A, Singh RP, Ramasamy K, et al. Growth inhibition and regression of lung tumors by silibinin: modulation of angiogenesis by macrophage-associated cytokines and nuclear factor-kappaB and signal transducers and activators of transcription 3. Cancer Prev Res (Phila). 2009; 2(1): 74-83. doi:10.1158/1940-6207.CAPR-08-0095
10.1158/1940-6207.CAPR-08-0095
CAS PubMed Web of Science® Google Scholar
100Velmurugan B, Singh RP, Tyagi A, Agarwal R. Inhibition of azoxymethane-induced colonic aberrant crypt foci formation by silibinin in male fisher 344 rats. Cancer Prev Res (Phila). 2008; 1(5): 376-384. doi:10.1158/1940-6207.CAPR-08-0059
10.1158/1940-6207.CAPR-08-0059
CAS PubMed Web of Science® Google Scholar
101Ibrahim A, Hugerth LW, Hases L, et al. Colitis-induced colorectal cancer and intestinal epithelial estrogen receptor beta impact gut microbiota diversity. Int J Cancer. 2019; 144(12): 3086-3098.
10.1002/ijc.32037
CAS PubMed Web of Science® Google Scholar
102Hases L, Indukuri R, Birgersson M, et al. Intestinal estrogen receptor beta suppresses colon inflammation and tumorigenesis in both sexes. Cancer Lett. 2020; 492: 54-62.
10.1016/j.canlet.2020.06.021
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume12, Issue4

February 2023

Pages 4367-4379

Implications of estrogen and its receptors in colorectal carcinoma

Abstract

1 INTRODUCTION

2 ROLE OF ESTROGEN RECEPTORS (ERS) IN CRC PATHOGENESIS

2.1 The expression characteristics of ERβ and ERα